Incidence of erythropoietin antibody-mediated pure red cell aplasia: The Prospective Immunogenicity Surveillance Registry (PRIMS)

Nephrology Dialysis Transplantation

Volumn 30, Issue 3, 2015, Pages 451-460

  Macdougall, Iain C ^a   Casadevall, Nicole ^b   Locatelli, Francesco ^c   Combe, Christian ^d   London, Gerard M ^e   Di Paolo, Salvatore ^f   Kribben, Andreas ^g   Fliser, Danilo ^h   Messner, Hans ⁱ   McNeil, John ^j   Stevens, Paul ^k   Santoro, Antonio ^l   De Francisco, Angel L M ^m   Percheson, Paul ⁿ   Potamianou, Anna ⁿ   Foucher, Arnaud ⁿ   Fife, Daniel ⁿ   Mérit, Véronique ⁿ   Vercammen, Els ⁿ  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c A MANZONI HOSPITAL   (Italy)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f R Dimiccoli Hospital Department of Gaastroenterology   (Italy)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MONASH UNIVERSITY   (Australia)

^k KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁿ JANSSEN RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

chronic kidney disease; darbepoetin alfa; epoetin alfa; epoetin beta; pure red cell aplasia

Indexed keywords

ERYTHROPOIETIN ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; AUTOANTIBODY; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ANTIBODY DETECTION; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSURVEILLANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURE RED CELL ANEMIA; REGISTER; SYRINGE; AGED; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; RED-CELL APLASIA, PURE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; AUTOANTIBODIES; DARBEPOETIN ALFA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RED-CELL APLASIA, PURE; REGISTRIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84924404728     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu297     Document Type: Article

References (25)

1. Pollock C, Johnson DW, Hörl WH et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199
2. Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406
3. Boven K, Knight J, Bader F et al. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20(Suppl 3): iii33-iii40
4. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48: 1754-1762
5. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003; 18(Suppl 8): viii37-viii41
6. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16(Suppl 1): S67-S69
7. Bennett CL, Luminari S, Nissenson AR et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-1408
8. Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353
9. Eprex® (epoetin alfa) Summary of Product Characteristics. Janssen Cilag. November 2012. http://www.medicines.org.uk/EMC/medicine/889/SPC/ Eprex+2000%2c+4000+and+10000+IU+ml+solution+for+injection+in+ pre-filled+syringe/ (14 February 2014, date last accessed)
10. Jacob A, Sandhu K, Nicholas J et al. Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant 2006; 21: 2963-2965
11. Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. Nephrol Dial Transplant 2007; 22: 1462-1464
12. Macdougall IC, Rossert J, Casadevall N et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009; 361: 1848-1855
13. Macdougall IC, Roger SD, de Francisco A et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesisstimulating agents: new insights. Kidney Int 2012; 81: 727-732
14. Jenke D. Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. PDA J Pharm Sci Technol 2002; 56: 332-371
15. Ryan MH, Heavner GA, Brigham-Burke M et al. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol 2006; 6: 647-655
16. Seidl A, Hainzl O, RichterMet al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2012; 29: 1454-1467
17. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia 'epidemic'-mystery completely revealed? Perit Dial Int 2007; 27(Suppl 2): S303-S307
18. Fotiou F, Aravind S, Wang PP et al. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 2009; 31: 336-346
19. Praditpornsilpa K, Kupatawintu P, MongkonsritagoonWet al. The association of anti-r-HuEpo-associated pure red cell aplasia with HLADRB1 09-DQB10309. Nephrol Dial Transplant 2009; 24: 1545-1549
20. Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: you can't fool Mother Nature. Kidney Int 2011; 80: 11-13
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266
22. Haag-Weber M, Eckardt KU, Hörl WH et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012; 77: 8-17
23. Verhelst D, Rossert J, Casadevall N et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004; 363: 1768-1771
24. Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001; 90: 1-11
25. Health Sciences Authority Dear Healthcare Professional Letters, October 2013 http://www.hsa.gov.sg/publish/hsaportal/en/health-products-regulation/ safety-information/DHCPL/2013.html, (14 February 2014, date last accessed)